Another blow to NASH, disappointing trial results spell end for darkhorse player Albireo
Another NASH program is headed to the scrap heap.
Albireo $ALBO, a Boston biotech that took an unconventional route to treating the fatty liver disease, announced yesterday that they were ending NASH development after they received disappointing results from a Phase II study. Just last week CEO Ron Cooper, on their Q2 call, talked up their offbeat approach and the potential for their lead molecule to be used in combination with agents now in development at other countries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.